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Creating first-in-class medications to treat human disease is an extremely challenging endeavor. While
genome sequencing and genetics are making direct connections between mutations and human disorders
at an unprecedented rate, matching molecular targets with a suitable therapeutic indication must ultimately
be achieved by pharmacology. Here, we discuss how the integration of chemical proteomic platforms (such
as activity-based protein profiling) into the earliest stages of the drug discovery process has the potential to
greatly expand the scope of proteins that can be pharmacologically evaluated in living systems, and, through
doing so, promote the identification and prioritization of new therapeutic targets.Introduction
Paradoxes abound in the modern world of drug discovery.
Genome sequences have provided a complete parts list
describing all of the proteins in the human body, and high-
throughput screening technologies offer platforms for exposing
these proteins to millions of small molecules. Yet as has been
well documented by others (Munos and Chin, 2011; Bunnage,
2011), such informational and technical advances have not yet
yielded a corresponding increase in new first-in-class medi-
cines. While the reasons for this are complex and multifold, we
will take the stance in this Perspective that at least part of the
problem with drug discovery today is that, for the critical step
of early stage target characterization in both academia and
industry, pharmacology has been largely displaced bymolecular
biology and genetics. This has created amethodological discon-
nect between the early (genetically driven) and late (pharmaco-
logically driven) stages of the drug development process that,
for the reasons outlined below, can impede and even prevent
the progression of potentially interesting therapeutic targets.
We argue that recent advances in chemical proteomic (‘‘chemo-
proteomic’’) methods should inspire a reintegration of pharma-
cology into the earliest stages of target characterization, such
that it serves as a driver for, rather than responder to, biological
discovery. Establishing a renewed commitment to pharma-
cology that is guided by modern chemoproteomic technologies
has the potential to create amuchmore efficient path tomine the
proteome for new drug targets.
Decades ago, pharmacology and the chemical probes that it
provides were integral to the process of biological discovery,
often providing the first insights into new protein targets and
biochemical pathways that affect mammalian physiology and
disease (Harding et al., 1989; Miller et al., 1990; Thornberry
et al., 1992; Swinney and Anthony, 2011). Many of these phar-
macological tools represented valuable ‘‘proof-of-relevance’’
probes, which we define for the purposes of this Perspective
as meeting the minimalist definition of compounds that can
block (or agonize) a protein of interest with good potency and
selectivity in both cell and animal models. Some of these phar-
macologically driven discoveries led to groundbreaking medi-
cines that are still used to treat human disorders today (SwinneyChemistry & Bioland Anthony, 2011). However, with the emergence of advanced
molecular biology methods in the late 1980s through the 1990s,
pharmacology somehow lost its sheen for early stage target
characterization, perhaps appearing as a somewhat cumber-
some approach that lacked the technical simplicity and speci-
ficity of genetic methods. In the ensuing decades, molecular
biology maintained and arguably even extended its dominion
over pharmacology, which was relegated to a much later step
in the target characterization pipeline that was only initiated
once substantial biological understanding of the protein
target had been achieved (usually through years of molecular
biology-driven research). This order of events brings us to the
here and now, where we are entering the second decade of
research since the first report of complete mouse and human
genome sequences, and yet we still lack proof-of-relevance
small-molecule probes for the vast majority of mammalian
proteins. Should this deficiency be attributed to the degree
of difficulty in developing such probes or a lack of firm com-
mitment to do so? We believe, perhaps not surprisingly, that
the answer is a combination of both, but also that the
second issue is more of a contributory factor than generally
realized.
No doubt about it—pharmacology is more difficult than
genetics. Each protein target, owing to its distinct structure
and function, presents a special set of challenges for chemical
probe development, and many have argued that only a small
fraction of the human proteome is even, in principle, ‘‘druggable’’
(Russ and Lampel, 2005; Overington et al., 2006). In contrast,
genetic methods have few if any target boundaries. The tech-
nical ease with which genes can be selectively knocked down
or out of cell and animal models is seductive, and rodent and
human genetics can further provide some of themost convincing
validation for target relevance to disease. However, genetic
disruption of a protein, which often results in the loss of protein
expression throughout life and is impractical for numerous
protein classes (e.g., developmentally essential genes), may
not mirror the effects of pharmacologically blocking its activity
in a mature organism. Several elegant inducible and tissue-
specific knockout/overexpression genetic systems have been
introduced in recent years to allow for more specific spatialogy 19, January 27, 2012 ª2012 Elsevier Ltd All rights reserved 11
Chemistry & Biology
Perspectiveand temporal control of gene expression; however, even these
systems do not fully recapitulate the diverse ways that pharma-
cological probes can modulate protein function. Many drugs, for
instance, produce their biological andmedical effects, as well as
avoid toxicity, by partial blockade (or activation) of a protein or by
targeting proteins in a subset of tissues. Drugs can also affect
multiple protein targets in vivo to produce therapeutic effects.
Modeling such partial target modulation or polypharmacology
by genetics is problematic.
Extrapolating from our knowledge of successful drugs and
their targets and mechanisms of action, one could argue that
pharmacology, no matter how challenging it may be, should be
placed front and center in any serious attempt to mine the pro-
teome for new drug targets. Ideally, one would like to generate
a proof-of-relevance small-molecule probe for every protein in
the mammalian proteome. The big question then becomes:
How can we best pursue this ambitious goal, especially in
today’s research environment, where the pharmaceutical in-
dustry, a historical juggernaut for developing first-in-class phar-
macological probes, is rapidly moving away from early stage
target discovery and validation (Munos and Chin, 2011; Bun-
nage, 2011)? As will be elaborated on below, we believe that
this change presents a tremendous opportunity for the academic
research community to create a new and more target-inclusive
approach to mammalian pharmacology. Emerging chemo-
proteomic methods offer ways to develop proof-of-relevance
probes for proteins that span the full spectrum of annotation to
include those with established activities and proteins that lack
functional annotation. Success could usher in a ‘‘back to the
future’’ era of scientific research where pharmacology once
again serves as a principal driving force for early stage biological
discoveries that, when coupled with insights into mechanism-of-
action provided by chemoproteomics, propel our understanding
of small-molecule effects on protein function in living systems.
This knowledge can then be used to prioritize new targets and,
perhaps more accurately, new drug-target pairs for clinical
development.
Genome Sequences as a Foundation for Modern
Pharmacology
One cannot overstate the importance of complete genome
sequences for modern approaches to pharmacology. We now
understand the full complement of proteins encoded by the
human genome (splice variants and posttranslationally modified
proteins excepted), and many human proteins can be grouped
into structurally and mechanistically related families based on
sequence homology. These complete protein families provide
a valuable starting point for asking an interesting set of pharma-
cological questions. Across how many protein families do
drugged targets distribute? Within these druggable families,
how many members have proof-of-relevance probes? For
probes that target multiple members of a given protein family,
is this polypharmacology reflected in simple sequence-related-
ness among the shared protein targets? Are protein families
that lack druggedmembers more difficult to target with chemical
probes, or do they simply represent portions of the proteome
that have not yet been experimentally investigated? Chemopro-
teomics is well-suited to address some if not all of these impor-
tant questions.12 Chemistry & Biology 19, January 27, 2012 ª2012 Elsevier Ltd All rChemoproteomics for Targeting Druggable but as yet
Undrugged Proteins
Several reviews and perspectives have discussed the topic of
the ‘‘druggability’’ of the human proteome (Russ and Lampel,
2005; Overington et al., 2006), often making the point that the
typical protein families considered most amenable to small-
molecule pharmacology (such as enzymes, channels, and re-
ceptors) represent only a modest fraction of all human proteins.
What is rarely mentioned in these perspectives, however, is what
fraction of the druggable proteome has already been drugged?
This is an important issue considering that the sum of all
enzymes, channels, and receptors in the human proteome likely
totals well over 2,000 proteins, a healthy number of candidate
drug targets by any account. To better grasp the current state
of our pharmacological coverage of the druggable proteome,
we consider two strategies that aim to discover chemical probes
for new protein targets: (1) chemoproteomics of large enzyme
families and (2) chemoproteomics combined with phenotypic
screening. Together, these approaches have generated the first
proof-of-relevance chemical probes for many enzymes, recep-
tors, and channels, while at the same time underscoring that
such probes are still lacking for a substantial fraction of the drug-
gable proteome. We discuss how chemoproteomic methods
can facilitate the completion of pharmacological maps for such
portions of the druggable but as yet undrugged proteome.
Chemoproteomics of Large Enzyme Families
Several of the largest protein families in humans, including
kinases, hydrolases, and oxidoreductases, are enzymes that
are related by a common mechanism and/or structure. The che-
moproteomic method activity-based protein profiling (ABPP)
targets the shared mechanistic and structural features of large
enzyme classes using active site-directed chemical probes to
create a versatile platform for enzyme and inhibitor discovery
(Cravatt et al., 2008). Here, we review how ABPP is being used
to develop proof-of-relevance inhibitors for enzymes using the
serine hydrolases as a case study.
Competitive ABPP to Develop Serine Hydrolase
Inhibitors
Serinehydrolases areoneof the largest andmost diverseenzyme
classes in nature, with more than 200 predicted members in
humans (Simon and Cravatt, 2010). Serine hydrolases are bound
together, not by sequence or structure, but by a common cata-
lytic mechanism that uses an activated serine nucleophile to
hydrolyze ester, thioester, or amide bonds in small-molecule,
peptide, and protein substrates. Individual serine hydrolases
have been found to perform vital biological functions in both
prokaryotic and eukaryotic organisms, including involvement in
bacterial cell wall biosynthesis, viral protein processing, blood
clotting, lipid metabolism, and termination of neurotransmitter
and hormone signaling (Long and Cravatt, 2011). Selective inhib-
itors have played prominent roles in the functional characteriza-
tion of serine hydrolases and, in several instances, been devel-
oped into drugs to treat human disorders such as diabetes
(Thornberry and Weber, 2007), obesity (Nelson and Miles,
2005), Alzheimer’s disease (Racchi et al., 2004), and bacterial
(Kluge and Petter, 2010) and viral (Vermehren and Sarrazin,
2011) infections. Based on these translational successes, one
might presume that pharmacology tools are available for a largeights reserved
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Indeed, we estimate that proof-of-relevance inhibitors have
been developed for less than 10% of the >200 human serine
hydrolases. This percentage does not appreciably increase if
one restricts the analysis to the more druggable 120 metabolic
serine hydrolases (i.e., removing from consideration the 120
trypsin/chymotryspin proteases, which somemay consider diffi-
cult to drug) (Figure 1A).
Given the biological importance and clinical relevance of
serine hydrolases, it is worth asking: Why do most enzymes
from this class still lack proof-of-relevance inhibitors? One
potential explanation is that the physiological functions for the
majority of mammalian serine hydrolases remain poorly charac-
terized (Simon and Cravatt, 2010; Long and Cravatt, 2011),
which could limit interest in targeting these enzymes for inhibitor
development. This is a classic ‘‘chicken and egg’’ problem,
where investment in pharmacology awaits deeper biological
knowledge, but acquiring this knowledge could itself depend
on the availability of pharmacological tools. Indeed, others
have noted that, for protein families such as the nuclear hormone
receptors, there is a direct relationship between the extent of
biological understanding of a protein (as estimated by publica-
tions on the protein) and whether a chemical probe exists for
this protein (Edwards et al., 2011). This relationship certainly
appears to hold true for serine hydrolases (Figure 1B), which
has motivated us to consider how to place pharmacology ahead
of biology for these enzymes, such that proof-of-relevance inhib-
itors can be developed to study the entire enzyme class,
including members that lack functional annotation.
Developing inhibitors for enzymes typically requires knowl-
edge of their substrates for assay configuration. This criterion
has historically hindered efforts to create full pharmacological
maps for large enzyme classes, such as the serine hydrolases,
that possess many uncharacterized members. In recent years,
however, chemoproteomic methods, such as ABPP, have
emerged to address this challenge. We have shown that
reporter-tagged fluorophosphonates (FPs) (Liu et al., 1999)
serve as activity-based probes for the vast majority of mamma-
lian serine hydrolases (Bachovchin et al., 2010). Competitive
ABPP can thus form the basis for a near-universal assay format
for serine hydrolase inhibitor discovery and optimization, where
small molecules are evaluated for their ability to block FP probe
labeling in a range of biological systems (Bachovchin et al.,
2010; Leung et al., 2003) (Figure 2A). Such competitive ABPP
programs might initiate with a high-throughput screen, where
the reaction between fluorophore-tagged FP probes and puri-
fied serine hydrolases is measured by fluorescence polarization
(fluopol, Figure 2A) (Bachovchin et al., 2009, 2011). Hits from
these screens are then immediately screened for activity and
selectivity in proteomes using gel-based or mass spectrom-
etry (MS)-based platforms for competitive ABPP (Figure 2B),
which collectively assay >50 serine hydrolases in parallel (Bach-
ovchin et al., 2011). An interesting output of these proteomic
assays is not only the rank-ordering of hits for the screened
enzyme target, but also the discovery of lead inhibitors for other
enzymes that were part of the counterscreen (Leung et al.,
2003). Lead compounds that show promising potency and
selectivity can be then be optimized through an iterative pro-
cess of medicinal chemistry and competitive ABPP, culminatingChemistry & Biolin candidate proof-of-relevance inhibitors that are ready for
in vivo testing.
Confirming inhibitor activity and selectivity in vivo can be chal-
lenging, especially for enzymes that lack known substrates or
product biomarkers. Here, we have found that competitive
ABPP can also serve an important purpose, where the tech-
nology is used to evaluate serine hydrolase activities in cells
and tissues from inhibitor-treated animals (Bachovchin et al.,
2011; Adibekian et al., 2011; Chang et al., 2011; Long et al.,
2009). Competitive ABPP thus enables the enzyme target to
serve as its own biomarker for inhibitor activity in vivo, allowing
for a direct and quantitative assessment of the extent and dura-
tion of target occupancy at a given dose of inhibitor. To be fair,
the ex vivo assessment of inhibitor activity by competitive
ABPP is technically more straightforward to perform with irre-
versible enzyme inhibitors (due to the stability of the covalent
enzyme-inhibitor interaction), but should also be applicable to
tight-binding reversible inhibitors that display slow off-rates.
Following the general competitive ABPP workflow outlined
above, proof-of-relevance inhibitors have been developed for
several serine hydrolases (Figure 1), and at least one of these
compounds has even progressed into human clinical trials (the
fatty acid amide hydrolase inhibitor PF-04457845 [Johnson
et al., 2011]). The targeted serine hydrolases belong to diverse
branches of the enzyme class and include both characterized
and uncharacterized members (Figure 1). Lead inhibitors have
also been identified for many additional serine hydrolases by
competitive ABPP (Bachovchin et al., 2010; Adibekian et al.,
2011), creating the first semblance of a pharmacological map
for this large enzyme class. Although still incomplete, this
map possesses multiple features that are informative for
family-wide inhibitor development programs. First, sequence
relatedness proves to be a rather poor predictor of shared phar-
macology among serine hydrolases (Bachovchin et al., 2010),
indicating that traditional strategies that involve counterscreen-
ing against the nearest sequence-neighbor enzymes may fail
to uncover important inhibitor cross-reactivity across large
enzyme classes. Second, competitive ABPP has identified sev-
eral mechanism-based chemotypes, such as the 1,2,3-triazole
urea (Adibekian et al., 2011) and aza-beta-lactam (Bachovchin
et al., 2011), that have not yet been extensively explored for
serine hydrolase inhibition. These chemotypes offer exciting
starting points for targeted libraries to improve pharmacological
coverage of the serine hydrolase class. Third, because compet-
itive ABPP provides a unifying assay for initial library screening,
hit optimization, and verification of inhibitor activity in vivo, inhib-
itor development programs have yielded proof-of-relevance
probes at an excellent pace (usually within 1-2 years of pro-
gram inception). The iterative feedback from competitive
ABPP assays in proteomes also expands the scope of probe
development across the serine hydrolase class by identifying
lead inhibitors for additional family members. In this way,
many inhibitor optimization programs can be launched and
progressed in parallel.
Chemproteomics Applied to Other Enzyme Classes
Competitive ABPP and additional chemoproteomic methods
have been used to assess inhibitor activity for many other
enzyme classes, including cysteine proteases, kinases, histone
deacetylases, and cytochrome P450s.ogy 19, January 27, 2012 ª2012 Elsevier Ltd All rights reserved 13
Pre-ABPP
Post-ABPP
Proof-of-Relevance
          Probe
B
A
Post-ABPP
Pre-ABPP
Proof-of-Relevance
          Probe
Figure 1. The Metabolic Serine Hydrolases as a Case Study for the Druggable, but Not Yet-Drugged Proteome
(A) Tree diagram showing the 115 human metabolic serine hydrolases. Enzymes possessing proof-of-relevance chemical probes developed prior to the
application of ABPP to serine hydrolases are marked with red arrows. Enzymes with proof-of-relevance probes discovered with ABPP platforms are marked with
blue arrows.
(B) Chart displaying metabolic serine hydrolases as a function of number of scientific publications, where enzymes possessing proof-of-relevance chemical
probes developed prior to or with the use of ABPP are marked in red and blue, respectively. Blue arrows are used to mark poorly characterized enzymes with low
publication number for which ABPP has generated proof-of-relevance probes.
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Figure 2. Representative Chemoproteomic
Platforms for Drug Discovery and
Development
(A) Competitive ABPP for high-throughput
screening of small-molecule libraries using fluo-
rescence polarization (fluopol) for hit discovery
and gel-based selectivity profiling in proteomes for
hit prioritization.
(B) SILAC-ABPP for quantitative assessment of
inhibitor selectivity in proteomes.
(C) Affinity enrichment combined with SILAC to
quantify small-molecule-interacting proteins from
native proteomes.
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develop selective inhibitors for the malarial cysteine proteases
falcipain-1 (Greenbaum et al., 2002), PfSU B1 (Arastu-Kapur
et al., 2008), DPAP1 (Deu et al., 2010), and DPAP3 (Arastu-Kapur
et al., 2008) and have shown that pharmacological blockade of
these enzymes impairs the malaria parasite’s life cycle.
Kinases, like serine hydrolases, are an extremely large and
diverse enzyme class with several hundred members in humans.
Several kinases, especially those with genetic ties to cancer
(Zhang et al., 2009), have been the focus of intense drug devel-
opment programs in the pharmaceutical industry, but in aggre-
gate, these only account for a modest fraction of all human
kinases. Academic and biotechnology researchers have begun
to fill in the pharmacological gaps in the kinome, often using che-
moproteomic methods to optimize the target selectivity of lead
inhibitors (Goldstein et al., 2008). Multiple strategies have been
introduced for this purpose, virtually all of which exploit the
conserved ATP binding pocket to create general assay plat-
forms. Examples of successful kinase inhibitor profiling plat-
forms include (1) phage-display screening of compounds forChemistry & Biology 19, January 27, 201competitive blockade of interactions
between kinases and immobilized non-
selective inhibitors (Fabian et al., 2005;
Davis et al., 2011), (2) MS screening of
compounds for competitive disruption of
interactions between kinases and immo-
bilized broad-spectrum inhibitors (Bant-
scheff et al., 2007; Ong et al., 2009), and
(3) ABPP of compounds for competitive
disruption of interactions between ki-
nases and acylphosphate-ATP probes
(Patricelli et al., 2007, 2011) (Figure 2B).
The latter two approaches, which use
MS to identify and quantify affinity-
enriched kinases, are distinguished by
their applicability to native proteomes,
which facilitates matching endogenous
kinase selectivity profiles with the cellular
activity for inhibitors. Analogous to the
aforementioned advances made with
serine hydrolases, academic and bio-
technology efforts have already begun
to deliver valuable proof-of-relevance in-
hibitors for poorly characterized kinases,
including RSK1 (Cohen et al., 2005,
2007), RIP1 (Degterev et al., 2008),TORC1/TORC2 (Feldman et al., 2009), MPS1 (Kwiatkowski
et al., 2010), BKM1 (Yang et al., 2010), LRRK2 (Deng et al.,
2011a), ERK5 (Deng et al., 2011b), Ack1 (Miduturu et al., 2011),
HIPK (Miduturu et al., 2011), NEK2 (Henise and Taunton,
2011), and isoform-selective PI3K inhibitors (Knight et al.,
2006). Interestingly, some of these inhibitors irreversibly inacti-
vate kinases by modifying noncatalytic active-site cysteine resi-
dues (Cohen et al., 2005; Henise and Taunton, 2011), which has
enabled their conversion into activity-based probes (Cohen
et al., 2007).
Multiple chemoproteomic strategies for profiling HDAC in-
hibitors have also been introduced, including the creation of
activity-based probes (Salisbury and Cravatt, 2007, 2008;
Fischer et al., 2011) and immobilized broad-spectrum inhibitors
(Bantscheff et al., 2011). Clickable, photoreactive activity-based
probes have been shown to label HDACs in living cells,
facilitating the discovery of HDAC activities that were impaired
upon cell lysis (Salisbury and Cravatt, 2007, 2008). These
ABPP studies also provided some of the first evidence that the
HDAC inhibitor SAHA, historically considered a pan-class I and2 ª2012 Elsevier Ltd All rights reserved 15
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3, and 6) (Salisbury and Cravatt, 2007), a finding that has been
confirmed with advanced substrate assays (Bradner et al.,
2010). Chemoproteomic enrichment of inhibitor-interacting
proteins has also identified unexpected specificity within
HDAC protein complexes and additional potential targets for
SAHA that are outside of the HDAC family (Fischer et al., 2011;
Bantscheff et al., 2011).
Activity-based probes for CYP450s, which have been synthe-
sized in clickable form to enable in vivo profiling (Wright and Cra-
vatt, 2007), have uncovered instances where clinically approved
drugs stimulate probe-labeling of individual CYP450s (Wright
et al., 2009). This ‘‘activation’’ may reflect heterotropic coopera-
tivity, a special feature of CYP450s, which can possess large
active sites capable of simultaneously binding multiple small
molecules.
Chemoproteomics for Target Discovery in Phenotypic
Screens
Cell-based phenotypic screening offers another powerful means
for developing proof-of-relevance chemical probes for proteins
(Swinney and Anthony, 2011). One potential advantage of cell-
based screening compared to the ‘‘protein family-centric’’
approaches mentioned above is that it can identify small-mole-
cule probes for a protein, or collection of proteins, that lack
robust biochemical assays. Connecting bioactive small mole-
cules emerging from cell-based screens with their protein
targets remains, however, a technically challenging endeavor
(Kasper et al., 2009). In recent years, chemoproteomic methods
have been introduced that are substantially improving the
success rate of target identification in small-molecule pheno-
typic screens. Affinity chromatography, wherein small molecules
are covalently attached to a solid support and used to ‘‘fish out’’
interacting proteins from cell lysates, is a well-established
method that has succeeded in identifying the protein targets of
many bioactive compounds, including natural products (Harding
et al., 1989; Taunton et al., 1996), enzyme inhibitors (Thornberry
et al., 1992; Cravatt et al., 1996), and hits from cellular screens
(Chen et al., 2006; Yagoda et al., 2007). However, historically,
these approaches have been limited by sensitivity and a lack
of quantitation. Chemoproteomic solutions have been intro-
duced to address these problems. First, modern MS methods
provide a tremendous boost in sensitivity such that even low-
abundance protein targets of small molecules can be identified.
MS methods can also be used to quantify the extent of target
enrichment by affinity chromatography, as elegantly demon-
strated by Ong et al. (2009) in their use of stable isotope labeling
with amino acids in cell culture (SILAC) to map the targets of
several small molecules (Figure 2C), including the kinase inhib-
itor K252a and the anticancer agent piperlongumine (Raj et al.,
2011). In both cases, multiple protein targets were identified
(kinases and a set of oxidative stress enzymes, respectively).
ABPP methods have also offered a chemoproteomic means to
detect, enrich, and identify the protein targets of bioactive small
molecules (Evans et al., 2005; Hall et al., 2011).
The use of chemoproteomic strategies for target characteriza-
tion in small-molecule phenotypic screens has yielded some
intriguing findings, including the realization that many bioactive
compounds appear to produce their pharmacological effects16 Chemistry & Biology 19, January 27, 2012 ª2012 Elsevier Ltd All rthrough modulating multiple protein targets (Chen et al., 2006;
Raj et al., 2011). That these protein targets can be unrelated by
sequence, structure, or function underscores the importance
of chemoproteomic methods that broadly survey the proteins
that bind to bioactive small molecules. It is also interesting to
note that, while many of the small molecules discovered in
cell-based screens represent the first proof-of-relevance probes
for their respective protein targets, the targets themselves typi-
cally belong to druggable classes of proteins (enzymes, chan-
nels, and receptors). In numerous cases where phenotypic
screens were employed to identify compounds capable of per-
turbing targets or pathways perceived to be ‘‘undruggable,’’
such as Ras (Yagoda et al., 2007), Wnt (Huang et al., 2009),
mutant p53 (Raj et al., 2011), and Sox2-mediated induced plurip-
otent stem cell induction (Ichida et al., 2009), the identified
compounds were shown to target enzymes or channels that
would be considered quite tractable by conventional drug
discovery efforts. Each of these efforts thus discovered new
pharmacological control points for historically challenging bio-
logical pathways, while at the same time underscoring the
considerable gaps that remain in our coverage of the druggable
proteome.
Summary: Reflecting Back and Projecting Forward
The contributions made to date by chemoproteomics to early
stage drug discovery can be grouped into a few general cate-
gories: (1) providing platforms for assaying small-molecule
libraries against poorly characterized members of large protein
classes; (2) optimizing the selectivity of lead probes by screening
against many proteins in parallel, often directly in native pro-
teomes and sometimes even in vivo; and (3) identifying the
protein targets for bioactive small molecules discovered in
phenotypic screens (Figure 3). The value of chemoproteomics
can also extend to later stages in the drug development process
by providing, for instance, a way to understand unanticipated
drug toxicities, as well as in vivo-biomarker assays that report
on target engagement in humans (Arastu-Kapur et al., 2011)
(Figure 3). There are certain portions of the proteome, such
as the hydrolases and kinases, where chemoproteomic
approaches have become integral components of the drug
development process and are helping to create proof-of-rele-
vance probes that span the full membership of these large
enzyme classes. This integration reflects, at least in part, the
advanced state of chemoproteomic technologies available to
profile these enzymes. Chemoproteomics has also become
a preferred method for addressing the dreaded ‘‘target identifi-
cation problem’’ in phenotypic screening programs, and can
even be used to more carefully reassess the proteins that
interact with drugs of purportedly known mechanisms of action.
Bearing such thoughts in mind, we propose a handful of direc-
tions where chemoproteomics could be taken to further advance
drug discovery.
Completing the Pharmacological Map of the Druggable
Proteome
An emerging theme from the family-centric and phenotypic
screening strategies discussed herein is the impact that chemo-
proteomics can have on developing first-in-class, proof-of-
relevance probes for the large number of proteins that fall intoights reserved
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Figure 3. How Chemoproteomics Can Enable Drug Discovery and Development from the Earliest Stages of Target and Lead Compound
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Shown are ways that chemoproteomics can assist the drug discovery and development process from early stage target and lead compound discovery through
lead optimization and biomarker analysis in preclinical and clinical development.
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is worth asking: Why were these druggable proteins, until
recently, lacking chemical probes? One possibility is that many
of these proteins were only discovered upon sequencing the
human genome and thus could not have been the focus of
medicinal chemistry efforts that predated this landmark event.
However, we do not believe that this explanation is satisfactory.
Take, for instance, the enzymes involved in glycolysis, which
were first characterizedmany decades ago.Most of the pharma-
cological tools used to perturb glycolytic enzymes consist of
low-affinity, broadly reactive chemotypes (e.g., alpha-keto-
halogens, arsenate salts) appended onto simplified substrate-
like scaffolds that are unlikely to exhibit suitable selectivity and
pharmacokinetic properties for in vivo biological studies
(Table S1). That specific glycolytic enzymes such as PKM2
(Christofk et al., 2008) and PGAM1 (Evans et al., 2005; Vander
Heiden et al., 2010) have nowmoved to the forefront as potential
anticancer targets only serves to underscore the frustrating gap
in our pharmacological toolbox to assess this classical metabolic
pathway. Fortunately, efforts are now underway to develop
proof-of-relevance probes for glycolytic enzymes (Walsh et al.,
2011), but we should be self-critical enough to ask retrospec-
tively: Why has it taken so long for these programs to kick into
action? We believe, as stated at the outset of this Perspective,
that the answer to the question is at least partly related to
the displacement of pharmacology by molecular biology andChemistry & Biolgenetics as modern approaches for perturbing protein function.
By pushing pharmacology back to the tail end of biological
discovery, we unnecessarily delay the creation of chemical
probes that could serve as valuable tools for assessing protein
function and translating this information into new medicines.
We recognize that there have been historical challenges asso-
ciated with the de novo discovery of useful small-molecule
probes in academic settings, but with the availability of public
screening centers and advancement of chemoproteomic
methods for target discovery and inhibitor optimization, these
issues have now largely been addressed. We therefore posit
that the infrastructure and technologies are in place to complete
our pharmacological map of the druggable proteome. Returning,
for instance, to glycolytic enzymes as an example. Many of these
enzymes possess aberrantly reactive nucleophilic residues
(Weerapana et al., 2010) and use cofactor-binding sites (e.g.,
ATP, NADH) that could be exploited for designing activity-based
probes to assist in assaying the activity and selectivity of inhibi-
tors. Lead inhibitors could also be evaluated for their selectivity
using the other chemoproteomic methods described in this
Perspective.
Discovery Biology through Pharmacology
As already demonstrated for kinases and hydrolases, the inte-
gration of small-molecule screening with chemoproteomics
can be extended to develop proof-of-relevance probes forogy 19, January 27, 2012 ª2012 Elsevier Ltd All rights reserved 17
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developing small-molecule probes for uncharacterized pro-
teins? The answer is at least 2-fold. First, these inhibitors,
when applied to cell and organism phenotypic assays, offer
powerful tools to discover the functions of proteins, as we
(Chiang et al., 2006) and others (Arastu-Kapur et al., 2008;
Yang et al., 2010; Deng et al., 2011a) have demonstrated. These
functional assignments can include elucidating the biochemical
pathways regulated by proteins (Chiang et al., 2006), as well as
the identification of specific diseases where probe-target pairs
might be progressed for drug development. Indeed, one only
need consider some of the most successful recent drug targets,
such as dipeptidylpeptidase IV (DPPIV) (Thornberry and Weber,
2007), for which proof-of-relevance inhibitors combined with
a simple glucose-tolerance test in rodents would have desig-
nated this enzyme as potential type 2 diabetes drug target.
Subsequent ‘‘peptidomic’’ studies could then be used to dis-
cover endogenous substrates of DPPIV (Tagore et al., 2009),
which might not only help to explain the pharmacological effects
of disrupting this enzyme, but also serve as pharmacodynamic
biomarkers for assessing its inhibition in human clinical studies.
DPPIV is also an interesting example because it represents
a validated drug target that, to our knowledge, lacks any direct
human genetic ties to diabetes. Thus, while human genetics
can certainly guide us to new drug targets, it should not, in our
opinion, be used blindly as a filter for this purpose, especially
at the risk of de-prioritizing druggable proteins from direct phar-
macological investigation in relevant disease models.
Even if initial phenotypic screens with a chemical probe fail to
reveal the biological activity of a protein, having such probes in
hand should enable rapid pharmacological confirmation of
functional assignments determined by other, complementary
approaches. Mouse and human genetic studies, for instance,
are linking missense, nonsense, and activating mutations in
protein-coding genes to disease at an increasing rate, but deter-
mining the mechanistic basis and translational relevance for
genotype-phenotype connections still depends on the avail-
ability of pharmacological probes. From a drug development
perspective, having proof-of-relevance chemical probes for
poorly characterized proteins thus sets the stage for ‘‘anticipa-
tory pharmacology,’’ wherein a genetic finding can be rapidly ex-
ploited for new medicines. An excellent example of anticipatory
pharmacology is crizotinib (Gadgeel and Bepler, 2011), an ALK
inhibitor that was recently approved for treating non-small cell
lung cancer (NSCLC). Crizotinib was originally developed as an
inhibitor of another kinase, c-Met (Zou et al., 2007); however,
upon the discovery that activating mutations in ALK are causa-
tive for a substantive fraction of NSCLCs (Soda et al., 2007),
crizotinib was quickly repurposed for treating this disease. In
this case, it was fortunate that crizotinib happened to inhibit
not only its originally intended target c-Met, but also ALK. As
a contrast, consider another enzyme, isocitrate dehydroge-
nase-1 (IDH1), for which activating mutations have also recently
been linked to cancer (Parsons et al., 2008; Dang et al., 2009).
Despite being a well-studied metabolic enzyme (first molecularly
characterized over a decade ago [Nekrutenko et al., 1998]) and
a putatively druggable protein, no inhibitors were available for
IDH1 at the time of its discovery as a cancer-relevant protein.
Progress toward validating IDH as a drug target must thus now18 Chemistry & Biology 19, January 27, 2012 ª2012 Elsevier Ltd All rawait the development of selective and in vivo-active inhibitors
for this enzyme. Considering that IDH1 belongs to a large family
of NADPH-dependent dehydrogenases, we anticipate that
chemoproteomicsmethods could play an important role in inhib-
itor optimization for this enzyme. More generally, ALK and IDH1
serve as interesting case studies to advocate for more system-
atic efforts to create proof-of-relevance chemical probes for
the entire druggable proteome, such that biological discoveries
linking these proteins to human disease can be rapidly translated
into new medicines.
Chemoproteomics for Purposive Polypharmacology
Crizotinib is one of several examples of multitarget kinase inhib-
itors that have been approved as therapeutics. In some cases, it
appears that the polypharmacological mechanism of action is
important for drug efficacy (Knight et al., 2010). The realization
that drugsoftenproduce their biological activity throughaffecting
multiple protein targets has inspired consideration of purposeful
polypharmacology as a way to develop new medicines (Parsons
et al., 2008; Knight et al., 2010; Boran and Iyengar, 2010). Con-
verting polypharmacology into a predictable science, however,
will require methods to fully assess the target profile of drugs in
complex biological systems, and, here, chemoproteomics
stands out as a particularly powerful approach. There are many
recent examples where chemoproteomics has helped to define
the set of proteins that are responsible for mediating the cellular
effects of bioactive smallmolecules. In somecases, the compen-
dium of targets belong to the same family of proteins (e.g., the
JQ1 and I-BET151 inhibitors of bromodomains (Delmore et al.,
2011; Dawson et al., 2011); the piperlongumine inhibitor of gluta-
thione S-transferases and related oxidative stress response
enzymes [Raj et al., 2011]), while in others, they show little or no
mechanistic or structural homology (e.g., the SC1 agent that
promotes embryonic stem cell self-renewal through targeting
both RasGAP and ERK1 proteins [Chen et al., 2006]). Chemopro-
teomics is particularly well-suited for uncovering such unantici-
pated cases of shared pharmacology that span unrelated protein
families. Once relevant target sets are defined, ensuingmedicinal
chemistry can focus on coordinately optimizing compounds to
maintain the desired target profile for drug action.
Chemproteomics for Mapping Protein Complexes
and Pathways
In addition to facilitating the characterization of direct targets of
bioactive small molecules, chemoproteomics can also lend
insights into the endogenous protein complexes that contain
these protein targets. This information can contribute to drug
discovery and target validation in several ways, including pro-
viding a more complete understanding of the composition of
complexes and pathways in which a protein of interest resides
and uncovering unanticipated specificity that chemical probes
might display for subcomplexes. Moulick et al. (2011), for
instance, employed affinity chromatography using small-mole-
cule probes and HSP90-specific antibodies to enrich HSP90-
containing protein complexes. This approach identified a known
HSP90 ‘‘client’’ oncoprotein in chronic myelogenous leukemia
cells, Bcr-Abl, as a preferentially associated protein in probe-
enriched but not immunoenriched HSP90 complexes. Further-
more, the abundance of HSP90-associated Bcr-Abl in a cellights reserved
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As HSP90 is known to associate with a variety of oncogenic
proteins (Trepel et al., 2010), chemoproteomic enrichment of
this chaperone in diverse cancers could be used as a method
to identify active oncogenic pathways and suitable therapeutic
options. A similar approach has been employed to identify the
protein targets and associated complexes of diverse classes of
HDAC inhibitors (Bantscheff et al., 2011). When coupled with
quantitative mass spectrometry, these studies revealed com-
pound specificity for not only the intended HDAC targets but
also HDAC-associated protein complexes, thus highlighting
the importance of assessing compound activity within endoge-
nous complexes, rather than in reconstituted in vitro systems.
Finally, a multifaceted, quantitative chemoproteomics approach
was recently used to identify protein-binding partners for several
bromodomain and extraterminal (BET) proteins in MLL fusion
leukemic cells (Dawson et al., 2011). Affinity-capture of BET
proteins with acetylated-histone peptides, BET-specific anti-
bodies, andBET-binding smallmolecules provided aquantitative
profile of BET-associated protein complexes, which included
a novel MLL fusion protein-containing transcriptional com-
plex. This insight provided a rationale to study the effects of
BET inhibitors in MLL fusion-positive cancer cells, which proved
highly sensitive to BET inhibition in vitro and in vivo. Each
of these examples highlights how chemoproteomics can
enrich our biological understanding of emerging drug targets
by mapping their connectivity to disease-relevant protein com-
plexes and pathways.
Chemoproteomics for Targeting Undruggable Proteins
Much of this Perspective has focused on the role that chemopro-
teomics can play in completing our pharmacological map of
the druggable proteome. We also believe, however, that the
described technologies can impact future efforts to develop
chemical probes for the undruggable proteome. New chemis-
tries, such as stapled peptides (Henchey et al., 2008) and
small-molecule mimetics of protein secondary structures (Berg
et al., 2002; Shahian et al., 2009), are emerging that enable phar-
macological perturbation of historically challenging protein
classes, such as transcription factor complexes (Berg et al.,
2002; Moellering et al., 2009; Emami et al., 2004), GTPases
(Patgiri et al., 2011), and apoptotic effectors (Walensky et al.,
2004; Bernal et al., 2007). Confirming target interactions and
selectivity for such agents in complex biological systems,
however, remains a difficult task. Many of the chemoproteomic
methods described herein should be amenable to addressing
this problem. Given the modular synthesis of peptides one could
consider, for instance, embedding within a stapled peptide
a photoreactive, clickable unit to enable crosslinking to protein
targets in living cells. Indeed, a similar approach was recently
employed to map the interaction surfaces of photoreactive,
stapled BH3 domain peptides in vitro (Braun et al., 2010). Like-
wise, the full complement of cellular proteins that interact with
a protein-protein interaction disrupter could be mapped using
affinity enrichment coupledwith SILACproteomics. The informa-
tion acquired in such chemoproteomic experiments would serve
to guide the optimization of drug activity and selectivity across
the proteome to accelerate the translation of emerging chemical
probes that target undruggable proteins into new medicines.Chemistry & BiolFurthermore, enrichment of protein complexes that contain
these targets could in principle identify alternative, more classi-
cally druggable sites for pharmacological intervention, as dis-
cussed above.
Conclusions
We began this Perspective with a stated goal of making an argu-
ment for the reintegration of pharmacology into early stage target
discovery programs. We believe that chemoproteomic methods
have matured to the point where they can efficiently guide the
development of proof-of-relevance chemical probes for a
substantial fraction of the human proteome. These probes
possess many important advantages over genetic approaches
for target perturbation, including the potential to disrupt protein
function in a temporally controlled manner and without affecting
protein expression, to partially activate or inhibit protein targets,
and to affect multiple protein targets in parallel. It is also instruc-
tive to recognize that protein classes, like hydrolases and ki-
nases, which have been a focal point of chemoproteomic inves-
tigations to date, also harbor some of themost rapidly expanding
suites of chemical probes. The unbiased nature of chemoproteo-
mic methods has even facilitated the development of probes for
uncharacterizedmembers of these enzyme classes (Bachovchin
et al., 2010; Miduturu et al., 2011; Li et al., 2007). We find this
contribution of chemoproteomics to modern pharmacology to
be particularly exciting in that it is delivering versatile chemical
probes that can be used to assign functions to proteins in virtu-
ally any biological model or system. Nonetheless, the majority of
human proteins, even those that reside within the druggable pro-
teome, still lack proof-of-relevance probes and addressing this
problem will require a more systematic approach to integrate
chemoproteomics, as well as other screening platforms that
evaluate small-molecule activity and specificity (Entzeroth
et al., 2000), into the basic fabric of pharmacology. We are skep-
tical that this integration can occur exclusively within the domain
of the pharmaceutical industry, which has been steadily moving
away from early stage drug discovery. Rather, we believe the
challenge (or opportunity, as we would prefer to view it) will
also need to be met by the academic research community.
Undoubtedly, continued collaboration between academic and
pharmaceutical institutions tomatch identified compound-target
pairs with relevant therapeutic indications will be necessary to
rapidly translate early-stage discovery efforts into new medi-
cines. By embracing the development of proof-of-relevance
chemical probes, and the continued advancement and imple-
mentation of chemoproteomic methods to ensure probe quality,
we should enjoy an era of pharmacology-driven biological dis-
covery that enhances the efficiency of converting basic knowl-
edge on protein and pathway function into new first-in-class
medicines to treat human disease.
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